Skip to content

Press Releases

Press Releases
All Releases
Nov 15, 2009
Plymouth, Michigan [13 November 2009] - Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that the company has initiated a Phase I clinical study for ETC-1002, the company’s novel small molecule compound designed...
= add release to Briefcase